---
title: Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter
  gene therapy improves survival of glioblastoma-bearing mice
date: '2023-09-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37701849/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230913180950&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: New treatment strategies are urgently needed for glioblastoma (GBM)-a
  tumor resistant to standard-of-care treatment with a high risk of recurrence and
  extremely poor prognosis. Based on their intrinsic tumor tropism, adoptively applied
  mesenchymal stem cells (MSCs) can be harnessed to deliver the theranostic sodium/iodide
  symporter (NIS) deep into the tumor microenvironment. Interleukin-6 (IL-6) is a
  multifunctional, highly expressed cytokine in the GBM microenvironment including
  recruited ...
disable_comments: true
---
New treatment strategies are urgently needed for glioblastoma (GBM)-a tumor resistant to standard-of-care treatment with a high risk of recurrence and extremely poor prognosis. Based on their intrinsic tumor tropism, adoptively applied mesenchymal stem cells (MSCs) can be harnessed to deliver the theranostic sodium/iodide symporter (NIS) deep into the tumor microenvironment. Interleukin-6 (IL-6) is a multifunctional, highly expressed cytokine in the GBM microenvironment including recruited ...